Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Researchers have uncovered novel insights into how brain function disruptions related to cerebrovascular disease (CeVD) ...

Lab-grown mini-brains help scientists explore how concussions reactivate latent viral infections, triggering molecular ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Activation of SIGMAR1 is expected to restore cellular homeostasis by inducing autophagy, which may slow neurodegeneration in patients with early AD.

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.